In bladder cancer patients, we validated that both chemotaxis and phagocytosis pathways (i.e., chemokine receptors bind chemokines and FcgR activation, respectively) are associated with immune infiltration in the PD-L1 treated bladder cancer cohort, using additional IHC-based results (Fig. 6). The gene discussed is FCGR2A; the disease is urinary bladder cancer.